Fakeeh Care Group Reports FY 2025 Revenue of SAR 3.1 Billion, Up 11% Year on Year; Attributable Net Profit reads SAR 290 Million, 1% Up Year on Year or 14% Excluding DSFH Madinah Ramp-Up Impact

FY-2025 Highlights[1]

Revenues	Gross Profit	Total Patients Served[2]
SAR 3,090.2 MN	SAR 704 MN	1,887,519
▲ 11% y-o-y	▲ 1% y-o-y / 23% margin	▲ 8% y-o-y
EBITDA[3]	**Net Profit**	**Attributable Net Profit**
SAR 496.3 MN	SAR 248.1 MN	SAR 290.2 MN
▼ 5% y-o-y / 16% margin	▼ 6% y-o-y / 8% margin	▲ 1% y-o-y

Gross Profit (Exc. DSFH Madinah)[4]	EBITDA (Exc. DSFH Madinah)[4]	Att. Net Profit (Ex. DSFH Madinah)[4]
SAR 763 MN	SAR 560 MN	SAR 332 MN
▲ 9% YoY / 25% margin	▲ 6% YoY / 18% margin	▲ 14% YoY

Jeddah, KSA, 04 March 2026: Dr Soliman Abdel Kader Fakeeh Hospital Company and its Subsidiaries ("Fakeeh Care Group", "FCG", "Fakeeh Care", the "Company" or the "Group"), a leading fully integrated academic healthcare provider listed on TASI (SYMBOL: 4017 and ISIN code SA562GSHUOH7), announces today its financial results[1] for the year ended 31 December 2025.

Key Financial & Operational Highlights

- **Revenue Growth Momentum Sustained:** Fakeeh Care Group generated **FY25 consolidated revenue of SAR 3.1 billion (+11% YoY)**, driven by higher contribution across the network as capacity scaled and demand converted into patients served. **Healthcare operations revenue reached SAR 2.8 billion (+10% YoY)** and represented **91%** of the top line, while **medical-related, education, and IT revenues totalled SAR 273 million (+16% YoY)**, reflecting continued expansion of the broader ecosystem around the core healthcare platform.

- **Patient Volume Growth and Higher-Acuity Mix:** The Group served **1.89 million patients in FY25 (+8% YoY)**. **Outpatients grew 8% YoY** and **inpatients grew 9% YoY**, while **surgical activity increased 9% YoY**, supporting continued case mix optimization toward higher-value, complex care.

- **Strong Utilization, With Strong Ramp Up Progress FY25:** Operational beds reached **544 in 4Q25** versus **457 in 4Q24**, reflecting scaling in DSFH Riyadh to **105 beds** and phased opening in DSFH Madinah to **66 beds**, while DSFH Jeddah remained stable at **373 beds while** Consolidated inpatient utilization averaged **81%** across FY25 despite the larger bed base.

---

[1] In accordance with the International Financial Reporting Standards (IFRS).
[2] The Group calculates Patients Served as the total of outpatients, inpatients, and home healthcare cases served during the period.
[3] The Group calculates EBITDA as Earnings Before Interest and Tax (EBIT) plus depreciation and amortization, and non-cash Long-term Incentive Plan (LTIP).
[4] The Group excludes all financials related to DSFH Madinah from the consolidated income statement in order to calculate these figures for management analysis purposes.

- **Mature Business Steady Performance:** Within healthcare operations, **Mature Business**, anchored by Jeddah based facilities, delivered **7% revenue growth in FY25** versus FY24 and accounted for **88% of healthcare revenue**, reflecting steady performance off a larger base. This was supported by sustained high utilization and disciplined throughput across the mature platform, while the Group's geographic diversification continued to progress through the scaling of the New Business cohort.

- **New Business Ramp Up and Capacity Expansion: New Business**, comprising DSFH Riyadh and DSFH Madinah, achieved **52% revenue growth in FY25** versus FY24 and accounted for the remaining **12% of healthcare revenue**. The growth was driven by **35% top-line growth at DSFH Riyadh** and the partial-year contribution from DSFH Madinah, which began operations in **2Q25**.

- **Gross Profit and Margin Dynamics:** FY25 gross profit remained broadly stable at **SAR 704 million**, supported by volume growth and continued case mix optimization. Gross margin moderated to **23%** versus **25%** in FY24, reflecting the ramp-up dilution from **DSFH Madinah**. **Excluding DSFH Madinah**, gross profit margin reads **25% in FY25, flat against FY24** highlighting that the underlying gross profitability of the established platform coupled with DSFH Riyadh remained intact.

- **Operating Profitability:** FY25 EBITDA was **SAR 496 million** versus **SAR 522 million** in FY24. **Excluding DSFH Madinah**, EBITDA in FY 25 was SAR 560 million at **18% margin in FY25** or 60bps lower from **FY24**, indicating a stable underlying operating profile while the new capacity continues to scale. **DSFH Riyadh** continued to improve through the year and turned EBITDA positive on a monthly level from September 2025, supporting a gradual narrowing of ramp up drag.

- **Net Profit and Attributable Earnings:** FY25 net profit after tax was **SAR 248.1 million** versus **SAR 263.7 million** in FY24. Profits attributable to shareholders were **SAR 290.2 million**, stable year on year with **EPS at SAR 1.26** versus **SAR 1.32** in FY24, considering a higher weighted average number of shares outstanding in FY25 versus FY24.

- **Balance Sheet, Liquidity, and Capital Deployment:** Capex invested in FY25 amounted to **SAR 529 million** as the Group progressed with the completion of DSFH Madinah, the medical centres in Jeddah and Makkah, and the Clinical Simulation Centre. Liquidity remained strong with **SAR 737 million** of liquid funds (cash **SAR 439 million** and government sukuk **SAR 298 million**). The Group remains in a **net cash position of SAR 106 million** on a cash-plus-sukuk basis.

- **Achievements Across the Integrated Healthcare Platform:** In FY25, DSFH Jeddah continued to strengthen third-party validation of its clinical governance and complex-care capability, including designation as a Pioneer Hospital under the Council of Health Insurance Daman program with a 110% score (setting a new national benchmark), the SRC Institutional Commitment to Excellence Award (first hospital globally), ongoing institutional reaccreditation by the Saudi Commission for Health Specialties since 2012, the CBAHI ACS certification (first private hospital in Saudi Arabia), and regional/international rankings by Newsweek and Statista for ambulatory care and specialized hospital performance.

Commenting on the Group's performance, FCG's President Dr. Mazen Soliman Fakeeh said:

"2025 was a year of disciplined delivery for Fakeeh Care Group. We closed the year with **SAR 3.1 billion** of revenue, up **11%** year on year, and served **1.89 million** patients, up **8% year on year**. The demand environment in Saudi healthcare remains supportive, but growth is only valuable when it is delivered with operational control. Throughout the year, we sustained broad-based throughput growth and continued to refine our clinical mix toward higher-value, complex care. We also expanded capacity across the network and progressed our geographic diversification, while maintaining high utilization and patient flow discipline across our ecosystem.

Our mature platform in Jeddah continues to anchor standards, clinical depth, and operating cadence. Our newer hospitals in Riyadh and Madinah are scaling access in catchments areas where demand is rising and complexity is underserved. We continue to treat expansion and growth as a capability build. That means embedding clinical governance, pathways, and service-line sequencing from day one, so that growth strengthens the Group's platform. This is how we build a national network with consistent outcomes.

During the year, our platform continued receiving external validation of our clinical governance and operating standards. DSFH Jeddah was designated as a Pioneer Hospital under the Council of Health Insurance Daman Classification program after scoring 110% against mandatory and optional criteria. This designation strengthens payor confidence and sets a new national benchmark for value-based care. We also built on our system-level approach to quality and we continued to progress recognitions that reinforce complex-care capability and patient safety standards. These milestones are not mere branding, they are evidence that our operating model is measurable, repeatable, and resilient as we expand.

Capability development in the Kingdom remains one of the defining priorities for the sector. Talent development is therefore a structural advantage for our Group. Through Fakeeh College for Medical Sciences, we continued to expand training capacity and strengthen clinical readiness, aligned with the Kingdom's localization agenda and long-term sustainability objectives. We view education and clinical development as core infrastructure. It protects standards as we scale, supports multidisciplinary delivery, and builds the pipeline required to meet rising demand without compromising quality.

Along with this, the Group's profits attributable to shareholders remained resilient at **SAR 290.2 million in FY25**, while **EPS was SAR 1.26 in FY25**, compared to **SAR 1.32 in FY24**, considering higher weighted average number of shares versus FY24. Normalizing for the newly opened DSFH Madinah impact on profitability, Attributable profits to shareholders were **SAR 332 million, up 14% year-on year**. This performance demonstrates the strength of the mature platform and provides further validation of the Group's expansion strategy in Riyadh as DSFH Riyadh advances through its ramp-up.

Looking ahead, we will keep building capacity and utilization while protecting the stable performance of the Group's Mature Business. We will continue to deepen tertiary capability where demand requires it. We will remain disciplined on operating cadence, governance, and capital allocation. Above all, we will keep scaling in a way that strengthens trust - trust from patients, payors, regulators, and shareholders who expect disciplined execution and clear accountability. With a resilient core, an expanding footprint, and a model increasingly validated across multiple geographies, Fakeeh Care Group is well positioned to create enduring value for patients, staff, students, shareholders, and the broader community."

Strategic Developments



- **Fakeeh College for Medical Sciences (FCMS):** The **6,500-sqm Simulation & Clinical Skills Centre** is complete and operating with **15 classrooms**, **12 labs**, and **18 OSCE rooms** capable of training **up to 500 students per day**. By pairing **immersive simulation** with rotations across the Group's hospitals, FCMS is building a pipeline of **practice-ready Saudi clinicians**, aligned with **Vision 2030** localization goals. Overall, the active student base continues to grow: **average number of students increased by 9% in FY25 compared to FY24**.

- **Top 10 Healthcare Providers in Saudi Arabia (Daman classification)**: DSFH Jeddah was classified as a **Pioneer Hospital** under the **Daman Classification** program by the Council of Health Insurance after scoring **110%** against mandatory and optional criteria. The designation reflects leadership in operational excellence and value-based performance, strengthening payor confidence while setting a **new national benchmark**.

- **Institutional Commitment to Excellence Award (SRC):** DSFH Jeddah received the Institutional Commitment to Excellence Award, becoming the **first hospital globally** to be awarded this recognition. The award reflects sustained institutional performance across quality systems, clinical governance, and execution consistency at scale**.**

CBAHI
المركز السعودي لاعتماد المنشآت الصحية
Saudi Central Board for Accreditation of Healthcare Institutions

- **CBAHI certification for Acute Coronary Syndrome (ACS) services:** DSFH Jeddah became the **first private hospital in Saudi Arabia** to receive CBAHI certification for ACS services. This certification reflects standardized, time-critical cardiac pathways and supports the hospital's positioning in complex emergency and tertiary cardiac care**.**

SAUDI ARABIA'S BEST AMBULATORY CARE CENTERS 2026 Newsweek statista

- **Saudi Arabia Best Ambulatory Care Centers 2026 (Newsweek):** Fakeeh Care Group was recognized among **Saudi Arabia's best ambulatory care centers** in Newsweek's 2026 ranking. The recognition highlights the strength of outpatient access and service quality across the ambulatory platform.

BEST SPECIALIZED HOSPITALS MIDDLE EAST 2026 Newsweek powered by statista

- **Best Specialized Hospitals Middle East 2026 (Newsweek & Statista):** DSFH Jeddah was ranked among the **best specialized hospitals in the Middle East** across **five key complex-care specialties**. This recognition supports the depth of tertiary capability and the hospital's ability to attract and retain complex case patients**.**

Operational Review

Fakeeh Care Group closed FY25 with strong operating momentum. The Group served **1.89 million patients** in FY25, up **8% YoY**. Growth was broad-based across the network. **Outpatients increased 8% YoY** and **inpatients rose 9% YoY** over FY25. **Surgical activity grew 9% YoY**, supporting continued case mix optimization toward higher-value, complex care. Patient care beyond facility premises also maintained its growth trajectory. **Home Healthcare cases served grew 8% YoY** in FY25, reinforcing the Group's continuity-of-care model.

Operational capacity expanded throughout the year and reached **544 beds in 4Q25**, compared to **457 beds in 4Q24**, reflecting a larger operating footprint. This included **105 beds at DSFH Riyadh**, the phased opening at **DSFH Madinah with 66 beds**, and stable capacity in **DSFH Jeddah at 373 beds**. Utilization remained strong despite the larger bed base. **Consolidated inpatient utilization reached 82% in 4Q25** and averaged **81%** across FY25.

The Group's Jeddah-based facilities and Home Healthcare represent the **Mature Business** and continued to deliver steady growth. Patients served reached **1.64 million in FY25**, up **4% YoY**, considering growth off a larger base. **DSFH Jeddah** utilization remained high and stable at **86% on average in FY25**. Operational performance continued to be supported by optimization programs focused on clinical pathway discipline, peri-operative scheduling, and discharge protocols that protect patient outcomes while sustaining high utilization and disciplined throughput.

The Group's **New Business**, which comprises **DSFH Riyadh and DSFH Madinah**, remained in ramp-up mode, with steep volume growth as capacity is added and service lines are scaled. **DSFH Riyadh** entered its high-growth phase in 4Q25. The hospital served **34% more patients in 4Q25** and **27% YoY growth** across FY25. With inpatient utilization reaching a record **85% in 4Q25**, DSFH Riyadh served **49% more inpatients** and **33% more outpatients** in 4Q25 versus 4Q24. For FY25, inpatients and outpatients served grew **32%** and **27%**, respectively. The hospital also continued to deepen higher-acuity service offerings throughout the year. **FY25 surgeries increased 77% YoY**, reflecting further specialty build-out and improving case mix.

DSFH Madinah progressed in line with the planned ramp-up and exhibited strong early momentum. Offered capacity reached **66 beds** by year-end. The hospital's trajectory steepened as patients served accelerated. Since opening in 2Q25, on a run-rate basis, patients served increased from around **650 patients per month** in 2Q25, to around **6,500 per month** in 4Q25. The increase in bed utilization from **2% in**

Total Patients Served



Total Operational Beds
(Beds/Occupancy %)



Outpatient Visits
('000)



Inpatient Admissions
('000)



2Q25 to **51% in 4Q25** is consistent with expanding access and early demand conversion as the hospital continues to scale.

Home Healthcare continued to support the ecosystem and continuity-of-care model. **FY25 patients served reached 34.4 thousand**, up **8% YoY**, while the platform supported discharge pathways, follow-up care, and patient access across the network.

Group Revenue
(SAR mn)



Healthcare Revenue Breakdown



COS Breakdown to Revenue
(SAR mn / % of revenue)



Financial Review

Fakeeh Care Group generated **revenue of SAR 3.1 billion in FY25**, up **11% YoY**. Revenue growth was driven by a higher contribution across the network as the Group continued to scale capacity and convert demand into volumes.

The Group's **healthcare operations** generated **SAR 2.8 billion** of revenue in FY25, up **10% YoY**, and accounted for **91%** of total revenue for the year. The remaining **9%** of revenue comprised **medical-related**, **education**, and **information technology (IT)** revenues, which together amounted to **SAR 273 million** in FY25 and grew **16% YoY**, reflecting continued expansion of the broader ecosystem around the core healthcare platform.

Within healthcare operations, the Group's **Mature Business**, anchored by the **Jeddah-based facilities**, generated **7%** revenue growth in FY25 versus FY24, reflecting steady performance off a larger base which accounts for **88%** of the Group's Healthcare revenue. The **New Business**, which comprises **DSFH Riyadh and DSFH Madinah** and accounts for the remaining **12%** of the Group's healthcare revenue, achieved **52%** revenue growth in FY25 versus FY24. This step-up was driven by **35% top-line growth at DSFH Riyadh** over the year, in addition to the partial-year contribution from **DSFH Madinah**, which began contributing to Group revenues from **2Q25** following its launch.

On a service-line basis, growth continued to be supported by the Group's higher-acuity activity. **Inpatient-related revenues grew faster than outpatient revenues in FY25**, consistent with rising surgical throughput and continued case mix optimization toward higher-value, complex care. This mix progression is an important driver of the Group's revenue.

Operating Costs Analysis

Over FY25, **absolute gross profit remained broadly stable at SAR 704 million** versus FY24, supported by higher volumes and continued case mix optimization. Gross profitability reflected the ramp-up dynamic as **revenue increased 11% YoY**, while **cost of sales grew 14% YoY**, taking **group gross margin to 23%** versus **25%** in FY24.

The growth in cost of sales was primarily driven by **Salaries & Related Benefits**, which reads **41% of revenue** in FY25 versus **38%** in FY24. As

Gross Profit
(SAR mn / Margin %)



EBITDA
(SAR mn / Margin %)



SG&A
(SAR mn / SG&A to Revenue %)



EBITDA Exc. Madinah
(SAR mn / Margin %)



the largest cost line, the increase reflected a combination of front-loaded clinical hiring and operating readiness costs in the ramping **DSFH Madinah**, alongside sector wage pressure and retention measures in a competitive market. By contrast, **materials and consumables were contained at 23% of revenue** in FY25 versus **24%** in FY24, while **other direct costs remained stable at 13%**, supported by procurement discipline, integrated sourcing, and continued standardization initiatives across the network.

The consolidated gross margin dilution was largely a function of ramp dynamics in **DSFH Madinah**, where manpower and fixed operating costs are carried ahead of full occupancy in the early phases of scaling. **DSFH Riyadh** is now in the later stages of its ramp and has improved cost absorption, supported by higher utilization and acuity, allowing it to cover its direct costs and reduce its dilutive effect on consolidated gross margin. **Excluding DSFH Madinah from the consolidation**, gross margin was **25% in FY25**, flat compared to **FY24**.

Operating Profitability analysis

Group EBITDA amounted to SAR 496 million in FY25, implying an **EBITDA margin of 16%**, compared to **SAR 522 million** and a **19%** margin in FY24. **Cash SG&As tracked network growth and commercial activation**, running at **12% of revenue** in both **FY25 and FY24**. Early benefits from centralizing non-medical functions helped contain costs.

The year-on-year movement in EBITDA largely reflects the dilution from the ramping **New Business**. The **New Business cohort (DSFH Riyadh + DSFH Madinah)** recorded an **EBITDA loss of SAR 25.8 million in 4Q25** and **SAR 118.3 million in FY25**. With **DSFH Riyadh turning positive EBITDA on a monthly basis in September**, Riyadh accounted for a **limited share** of the New Business EBITDA loss. As a result, **the consolidated EBITDA margin dilution was primarily driven by DSFH Madinah**, where under-absorbed clinical staffing and start-up overhead were carried ahead of full occupancy during the early stages of ramp-up.

When **excluding DSFH Madinah** from the consolidation, the Group generated **SAR 139 million of EBITDA in 4Q25** and **SAR 560 million in FY25.** EBITDA margin was **18% in 4Q25** versus **16% in 4Q24**, and **18% in FY25** just 60 bps below **FY24**. On this basis, the 60 bps margin movement is mainly attributed to (i) **Hajj project deployment that took place in 2Q25**, which was delivered at a lower margin than the Group average and (ii) **margin normalization in the NEOM O&M contract**, which remained accretive but less so than in 2024.

The earnings algorithm remains intact. The mature platform, excluding **DSFH Riyadh** and **DSFH Madinah**, continues to deliver an EBITDA margin above **22%**. As **DSFH Riyadh's** contribution continues to build and utilisation rises across the New Business, ramp drag should progressively narrow and consolidated dilution should soften, supporting sequential margin stabilisation in the near term.

Net Profit

Group net profit after tax was **SAR 248.1 million in FY25**, compared to **SAR 263.7 million in FY24** and reflects the same ramp dynamics discussed earlier, which offset strong volume growth and lower finance costs.

FY25 Net Profit Bridge (SAR mn)



Net Profit
(SAR mn / Margin %)



The year-on-year movement in FY25 net profit is best explained through the net profit bridge above from FY24 to FY25. **FY25 net profit** was supported by a **SAR 27.3 million uplift from the Mature Business** and a **SAR 45.3 million uplift from DSFH Riyadh** as it progressed further along its breakeven trajectory. These positives were more than offset by **DSFH Madinah's ramp impact of SAR (75.8) million**, alongside **incremental provisions of SAR (10.9) million** and a **SAR (1.4) million impact from margin normalization in the NEOM O&M contract.**

Attributable Profits
(SAR mn)



Profits attributable to shareholders remained resilient at **SAR 290.2 million in FY25**, stable year-on-year, reflecting the allocation of losses to non-controlling interests. **EPS was SAR 1.26 in FY25**, compared to **SAR 1.32 in FY24**, reflecting the higher weighted average number of shares outstanding in FY25 versus FY24.

Cash Balances*
(SAR mn)



**Cash as of Dec 2025 & Dec 2024 include Sukuk amounting to SAR 298.1mn & SAR 196mn respectively*

Balance Sheet, Liquidity & Capital Deployment

Total assets as at **31 December 2025** stood at **SAR 5.83 billion**, up **10%** versus year-end 2024 (**SAR 5.32 billion**). The increase reflects continued capital deployment into network expansion, consistent with the year's investment cycle.

Total capex invested in FY25 amounted to **SAR 529 million** (including intangible assets), as the Group progressed with the completion of



In Dec. 24 the Group reported Net Cash of SAR 193 million, in Dec. 25 the Group reported Net Cash of 106 million.

Madinah Hospital, the **medical centers in Jeddah and Makkah**, and the **Clinical Simulation Centre** which is now complete.

The Group retained meaningful liquidity headroom. **Cash and cash equivalents were SAR 439 million**, while **government sukuk holdings were SAR 298 million**, taking total liquid funds to **SAR 737 million**, broadly stable versus year-end 2024. This liquidity profile supports the Group's growth initiatives within current balance sheet capacity. Total loans (short- and long-term) were **SAR 632 million** at year-end 2025 (FY24: **SAR 537 million**). As a result the Group remained in a **net cash position of SAR 106 million** when netting loans against cash and sukuk holdings (FY24: **SAR 193 million** net cash) and retains meaningful liquidity headroom for its growth initiatives, within current balance-sheet capacity.

– Ends –

About Fakeeh Care Group

Established in 1978 by the late Dr. Soliman Fakeeh, the Fakeeh Care Group stands as a pioneer in integrated healthcare services in Saudi Arabia. Our comprehensive healthcare offering includes our core healthcare services ranging from ambulatory care to secondary and tertiary care, supported by Emergency Medical Services and Fakeeh Home Healthcare. Additionally, our offerings are enhanced by our industry-leading academic healthcare programs. Building on a strong track record of growth in our home city of Jeddah, the Group embarked on a Kingdom-wide expansion strategy to bring our well proven hub-and-spoke model and medical support services to major cities across Saudi Arabia.

In June 2024, Fakeeh Care Group successfully concluded its initial public offering (IPO) on the Tadawul. The IPO raised gross proceeds of SAR 2.9 billion (US$ 764 million) for the Company and the Selling Shareholders of which SAR 1.7 billion will be used to support and accelerate the Group's growth strategy.

For further information, please contact:

Mr Waleed Hamed
Investments & Investor Relations Director
Email: wahamed@fakeeh.care

Mr Panagiotis (Panos) Chatziantoniou
Vice President, Group Investments and Treasury
Email: investors@fakeeh.care

Forward-looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "anticipates", "assumes", "believes", "could", "estimates", "expects", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would", or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding the Company's business and management, its future growth or profitability and general economic and regulatory conditions and other matters affecting it.

These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and its investments, including, among other things, the development of its business, financial condition, prospects, growth, strategies, as well as the trends in the industry and macroeconomic developments in the Kingdom of Saudi Arabia. Many of these risks and uncertainties relate to factors that are beyond the Company's control or accurate estimation, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and any changes in applicable laws or regulations or government policies. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not otherwise occur and past performance shall not be taken as a guarantee of future results. No representation or warranty is made pertaining to any forward-looking statement made by the Company. The Company does not intend to update, supplement, amend or revise any such forward-looking statement whether as a result of new information, future events or otherwise. Nothing in the Information shall be construed as a profit forecast.

The Information may include financial information that are not defined or recognized under the International Financial Reporting Standards (IFRS). These measures are derived from the Company's consolidated financial statements and provided as additional information to complement IFRS measures. Any financial information provided by the Company should not be considered in isolation or as a substitute for analysis of the Company's financial information as reported under the IFRS.

Consolidated Income Statement

SAR millions	FY-2025	FY-2024	YoY %
Revenue	3,090.2	2,790.9	11%
Costs of revenue	(2,386.4)	(2,091.8)	14.1%
Gross profit	**703.9**	**699.0**	**0.7%**
Gross profit margin	***22.8%***	***25.0%***	***-2.3pp***
Other income	14.9	11.2	32.8%
General and administrative expenses	(299.4)	(278.5)	7.5%
Selling and marketing expenses	(80.9)	(59.2)	36.7%
Long-term Incentive Plan	(6.0)	0.0	-
Impairment loss on receivables	(24.4)	(13.5)	81.2%
Operating profit	**308.0**	**359.1**	**-14.2%**
Operating Profit margin	***10.0%***	***12.9%***	***-2.9pp***
Finance cost	(48.8)	(95.7)	-48.9%
Finance income	21.3	23.7	-10.0%
Profit before Zakat	**280.5**	**287.1**	**-2.3%**
Zakat	(32.3)	(23.4)	38.2%
Profit after Zakat	**248.1**	**263.7**	**-5.9%**
Profit margin	***8.0%***	***9.4%***	***-1.4pp***
Profit for the year attributable to:			
Shareholders' of the Company	**290.2**	**287.6**	**0.9%**
Non-controlling interest	(42.1)	(23.9)	76.1%
Additional information:			
EPS[1]	1.26	1.32	-4.7%
EBITDA	**496.3**	**521.9**	**-4.9%**
EBITDA margin	***16.1%***	***18.7%***	***-2.6pp***

[1] *Earnings per share (EPS) is calculated based on attributable net profit and the weighted average number of shares which reads 230,000,000 shares for FY25, and 217,178,082 for FY24*

Consolidated Balance Sheet

SAR 000'	31-Dec -25	31-Dec-24
ASSETS		
Property and equipment	2,498,755	2,095,843
Right-of-use assets	492,247	505,338
Intangible assets and goodwill	547,568	543,980
Investment properties	376	417
Financial asset at amortized cost	298,126	195,604
Prepayments and other non-current assets	22,244	15,024
Other long-term receivables	144,748	117,716
Non-current assets	**4,004,064**	**3,473,922**
Inventories	196,293	178,727
Accounts and other receivables	974,978	895,520
Contract assets	39,798	68,549
Prepayments and other current assets	174,382	171,122
Cash and cash equivalents	439,162	533,785
Current assets	**1,824,613**	**1,847,703**
TOTAL ASSETS	**5,828,677**	**5,321,625**
EQUITY		
Share capital	232,000	232,000
Treasury shares	(2,000)	(2,000)
Share premium	1,653,473	1,653,473
Retained earnings	1,288,560	1,061,873
Equity attributable to shareholders of the Company	**3,172,033**	**2,945,346**
Non-controlling interests	409,353	374,078
Total equity	**3,581,386**	**3,319,424**
LIABILITIES		
Long-term loans	334,000	321,500
Lease liabilities	481,162	481,208
Employees' end of service benefits	312,996	260,689
Non-current liabilities	**1,128,158**	**1,063,397**
Short-term loans	297,543	215,000
Current portion of lease liabilities	63,662	60,186
Accounts payables	362,234	372,900
Accrued and other current liabilities	365,403	265,234
Accrued zakat	30,291	25,484
Current liabilities	**1,119,133**	**938,804**
Total liabilities	**2,247,291**	**2,002,201**
TOTAL EQUITY AND LIABILITIES	**5,828,677**	**5,321,625**
Additional information:		
(Net Cash) Net Debt	(105,745)	(192,890)
Total debt (including leases)	439,079	348,505
Net Debt / Equity	(0.030)	(0.058)
Total Debt / Equity	0.123	0.105
12 months rolling EBITDA	496,326	521,948
Net Debt / EBITDA	(0.213)	(0.370)
Total Debt / EBITDA	0.88	0.67